Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Allos Therapeutics, Inc. (MM) Charts. Click Here for more Allos Therapeutics, Inc. (MM) Charts.](/p.php?pid=staticchart&s=N%5EALTH&p=8&t=15)
Allos Therapeutics Files Shelf Registration Statement
WESTMINSTER, Colo., March 5 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc.
announced today that it has filed a Form S-3 shelf registration with the
Securities and Exchange Commission (SEC). The shelf registration, when declared
effective by the SEC, will allow the company to raise up to $75 million through
the sale of various securities in one or more offerings in the future. Specific
terms and prices will be determined at the time of any offering.
A registration statement relating to the securities listed in the shelf
registration has been filed with the SEC, but has not yet become effective.
These securities may not be sold, nor may offers to buy such securities be
accepted, prior to the time that the registration statement becomes effective.
This press release shall not constitute an offer to sell or the solicitation of
an offer to buy, nor shall there be any sale of these securities, in any state
in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state.
A written prospectus, when available, meeting the requirements of Section 10 of
the Securities Act of 1933, as amended, may be obtained fromthe company at
11080 CirclePoint Road, Suite 200, Westminster, Colorado 80020, Attention:
Investor Relations.
Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing
and commercializing innovative drugs for improving cancer treatments. The
company's lead clinical candidate, RSR13, is a synthetic small molecule that has
the potential to sensitize hypoxic (oxygen deprived) tumor tissues and enhance
the efficacy of standard radiation therapy. In addition, Allos is developing
PDX, an injectable small molecule chemotherapeutic agent that has a superior
potency and toxicity profile relative to methotrexate and other dihydrofolate
reductase, or DHFR, inhibitors. For more information, please visit the
company's web site at: http://www.allos.com/.
This news release contains certain forward-looking statements that involve risks
and uncertainties. Such forward-looking statements include statements regarding
the sale of securities under the shelf registration statement. Such statements
are only predictions and the company may be unable to complete any sale of
securities under the shelf registration statement. Factors that may cause such
differences include market conditions and others that are more fully discussed
in the company's periodic reports and other filings with the SEC.
DATASOURCE: Allos Therapeutics, Inc.
CONTACT: Monique M. Greer VP, Corporate Communications and Investor
Relations of Allos Therapeutics, Inc., +1-720-540-5241,
Web site: http://www.allos.com/